PHARMACY

Walgreens takes 90-day prescription program to Raleigh

BY Allison Cerra

RALEIGH, N.C. One week after promoting its 90-day prescription program in Minneapolis, one of the nation’s largest drug store chains is taking its initiative to Raleigh, N.C.

Walgreens said Monday that through its 90-day prescription program, eligible patients in Raleigh will be able to receive certain medications in 90-day supplies from their local Walgreens pharmacy and their trusted community pharmacist, as an alternative to delivery from a mail-order pharmacy. Walgreens pharmacists will begin reaching out to physicians and eligible patients in Raleigh to educate them on the benefits of a 90-day prescription program, the company said.

Last week, the drug store chain announced its promotion of the program in community area pharmacies in Minneapolis.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Mission launches Uribel

BY Alaric DeArment

SAN ANTONIO Drug maker Mission Pharmacal has launched a treatment for urinary tract infections.

 

Mission announced the launch of Uribel (methenamine, sodium phosphate monobasic, phenyl salicylate, methylene blue and hyoscyamine sulfave) capsules, used to relieve local discomfort and inflammation associated with lower urinary tract infections, interstitial cystitis, painful bladder syndrome and urinary tract procedures.

 

 

Mission will handle distribution and marketing of Uribel for Star Pharmaceuticals, while an unnamed third party company will manufacture the drug.

 

 

“Uribel is an important expansion of our urology and women’s health product portfolio, and we’re excited to be partnering with Star Pharmaceuticals to bring this product to patients,” Mission president of commercial operations Terry Herring said. “Uribel provides three complementary ways to treat uncomfortable urinary tract conditions – an analgesic to relieve pain and burning, an antispasmodic to reduce urinary urgency and antiseptic that inhibits the growth of bacteria.”

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Genzyme, Isis announce study results for mipomersen

BY Alaric DeArment

CAMBRIDGE, Mass. Biotech company Genzyme and Isis Pharmaceuticals have finished late-stage clinical trials of a cholesterol-lowering drug, the two companies said.

Genzyme and Isis announced results of two phase 3 studies of the drug mipomersen in patients who have high cholesterol levels while taking high doses of cholesterol-lowering medications. The studies were conducted in North America, Europe and South Africa.

In one study of patients with severe hypercholesterolemia, mipomersen reduced “bad” LDL cholesterol by 36%, compared with 13% among those taking placebo; in the other study of patients with high cholesterol at high risk of cardiovascular disease, the drug reduced LDL cholesterol by 37%, compared with 5% among those taking placebo.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?